ABL1 and leukemia: We utilized a mouse model of BCR-ABL-positive leukemia to examine the in vivo effects of SDF-1 inhibition by NOX-A12 (40 mg/kg every other day administered subcutaneously (sc)), combined with the ABL inhibitor, nilotinib, administered by oral gavage.